



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: J. Henkin, et al.

Serial NO.: 09/832,733

Filed: April 11, 2001

Title: PEPTIDE ANIANGIOGENIC
DRUGS

Case No.: 6356.US.03

Group Art No.: (not yet
assigned)

Examiner: (not yet assigned)

I hereby certify that this paper (along with
any paper referred to as being attached or
enclosed) is being deposited with the United
States Postal Service on the date shown below
with sufficient postage as first class mail in
an envelope addressed to the:

Assistant Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: May 18, 2001

Tanya Benavidez 5/18/01
Tanya Benavidez Date

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

This submission does not represent that a search has been made or that no better art exists, and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to


the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

ABBOTT LABORATORIES
D-0377/AP6D-2
100 Abbott Park Road
Abbott Park, IL 60064-3500
Telephone: (847) 937-0042
Facsimile: (847) 938-2623

Respectfully submitted,
J. Henkin, et al.



Gregory W. Steele
Registration No. 33,796
Attorney for Applicants



DATE: May 18, 2001

SHEET 1 of 1

Form PTO-1449 (Modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6356.US.03

SERIAL NO.

09/832,733

APPLICANT(S)

J. Henkin, et al.

FILING DATE

April 11, 2001

GROUP

(not yet assigned)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	5,190,918	03/02/93	Duetch, et al.			
	A2	5,192,744	03/09/93	Bouck, et al.			
	A3	5,200,937	04/06/93	Deutch, et al.			
	A4	5,426,100	06/20/95	Deutch, et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION
	B1	0443404A	28.08.91	EPO			YES NO
	B2	9316716A	02.09.93	WO			
	B3	9741824A	13.11.97	WO			
	B4	9841542A	24.09.98	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Donoviel, <i>J. Biological Chemistry</i> , 263:18590-18593 (1988)
C2	Gasparini, et al., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More than a New Prognostic tool," <i>Journal of Clinical Oncology</i> 13(3):765-782
C3	Haverstick, et al., <i>Biochemistry</i> , 23:5597-5603
C4	Hennessy, et al., <i>J. Cell Biology</i> , 108:729-736 (1989)
C5	Lawler and Hynes, <i>J. Cell Biology</i> , 103:1635-1648 (1986)
C6	Majack and Bornstein, <i>Cell Membranes Methods-Reviews</i> , 3:55-77
C7	Santoro and Frazier, <i>Methods of Enzymology</i> , 144:438-446 (1987)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)